



## **36th ANNUAL CONVENTION**

American Association of Bovine Practitioners Columbus, Ohio September 18-20, 2003







©2003 Pfizer Inc ADV03059

0

Help your clients send more cattle back to the home pen by recommending A180<sup>™</sup> (danofloxacin mesylate). Its unique chemistry rapidly delivers a high level of drug directly to diseased lung tissue, speeding recovery from BRD.<sup>1,2</sup> In fact, 87% of cattle treated with A180 responded positively in controlled field trials—even in cases of severe BRD.<sup>4</sup> When you factor in low-dose volume, sub-Q administration and a 4-day withdrawal period, isn't A180 worth your serious consideration? Note: Extra-label use is prohibited in food-producing animals.

Call 1-800-USE-A180 for a complete A180 Information Kit.

'A180 Freedom of Information (FOI) Summary 'Pfizer study #5131C-03-98-198 'TerHune, et al. XXII World Bulatric Congress. Hannover Germany 2002. 'A180 FOI Summary. Figure stated represents an average cure rate among clinical studies. 'A180 and Baytril FOI Summaries. A180° is a trademark of Pfizer Inc. Baytril® is a registered trademark of Bayer Corporation. See adjacent page for detailed product information. ISSN 0524-1685





EDITOR: ROBERT A. SMITH, DVM 3404 Live Oak Lane Stillwater, Oklahoma 74075 Tel: (405) 372-8666 FAX (405) 743-8422 PRINTER: Frontier Printers, Inc. 205 W. 9th Stillwater, Oklahoma 74074

### OFFICERS

President	
	Lexington, Kentucky
President-Elect	Mark Spire, DVM
	Manhattan, Kansas
Vice President	Rich Meiring, DVM
	Marysville, Ohio
Past President	
	East Lansing, Michigan
Executive Vice President	James A. Jarrett, DVM
	Rome, Georgia
Treasurer	Mark Wustenberg, DVM
	Bay City, Oregon
Parliamentarian	
	Auburn, Alabama

#### **BOARD OF DIRECTORS**

Roger Saltman, DVM Cazenovia, New York 1st District, 2005 Darcie J. Stolz, DVM Strasburg, Pennsylvania 2nd District, 2003 Charlie Hatcher, DVM College Grove, Tennessee 3rd District, 2004 Michael Bolton, DVM Greenville, Michigan 4th District, 2005 Andy Johnson, DVM Seymour, Wisconsin 5th District, 2003 Steve Stewart, DVM Woodbury, Minnesota 6th District, 2004 Wade Taylor, DVM Oakley, Kansas 7th District, 2005 Charlie E. Deyhle, Jr., DVM Canyon, Texas 8th District, 2003 Jim Wasson, DVM Armour, South Dakota 9th District, 2004

Alan Herring, DVM Litchfield Park, Arizona 10th District, 2005 Gregory A. Ledbetter, DVM Jerome, Idaho 11th District, 2003 Reny Lothrop, DVM Cambridge, Ontario, Canada 12th District, 2004 Sjoert Zuidhof, DVM Lethbridge, Alberta, Canada 13th District, 2005

James A. Jarrett, DVM

(alternate)

#### REPRESENTATIVE TO THE AVMA HOUSE OF DELEGATES:

Darrel E. Johnson, DVM Weyauwega, Wisconsin EXHIBITS MANAGER:

\_\_\_\_\_

### ADVERTISING AGENCY:

Samuel Hutchins, III, DVM South Barre, Vermont J. T. O'Brien & Assoc. 12118 Nieman Road Overland Park, KS 66213 913-402-8383 Fax: 913-897-9047

THE BOVINE PRACTITIONER is published by the American Association of Bovine Practitioners, Inc., at Frontier Printers, 205 W. 9th, Stillwater, OK 74074 (Tel: 405-372-8500; FAX 405-372-8523). Over 6000 copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to: Dr. James A. Jarrett, Exec. Vice President, AABP, P.O. Box 1755, Rome, GA 30162-1755 Tel: 1-800-269-2227; FAX 706-232-2232 e-mail: aabphq@aabp.org

http://www.aabp.org

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in February and June annually. It also serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English.

Copies of THE BOVINE PRACTITIONER are available to non-members for \$25.00 per copy, surface mail, or \$33.00, airmail (overseas). Contact editor for details.

©American Association of Bovine Practitioners, 2003 • All Rights Reserved • The Bovine Practitioner • ISSN 0524-1685

Vol. 37, No. 2 June, 2003



#### Sterile Antimicrobial Injectable Solution

180.0 mg of danofloxacin as the mesylate salt/mL For subcutaneous use in cattle only

Not for use in cattle intended for dairy production or in

calves to be processed for yeal.

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Federal law prohibits the extra-label use of this drug in food-producing animals.

INDICATIONS: A180 (danofloxacin mesylate) injectable solution is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia (Pasteurella) haemolytica and Pasteurella multocida.

DOSAGE AND ADMINISTRATION: A180 is administered as a subcutaneous dose of 6 mg/kg of body weight (1.5 mL/100 lb). Treatment should be repeated once approximately 48 hours following the first injection. Care should be taken to dose accurately. Administered dose volume should not exceed 15 mL per injection site.

WARNINGS: Animals intended for human consumption must not be slaughtered within 4 days from the last treatment. Do not use in cattle intended for dairy production. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

HUMAN WARNINGS: For use in animals only. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. To report adverse reactions or to obtain a copy of the Material Safety Data Sheet, call 1-800-366-5788.

III 1-000-300-3200.

**PRECAUTIONS:** The effects of danofloxacin on bovine reproductive performance, pregnancy, and lactation have not been determined.

Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.

Quinolone-class drugs should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation, which may lead to convulsive seizures.

Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature, rapidly growing animals of various species. Refer to Animal Safety for information specific to danofloxacin.

ADVERSE REACTIONS: A hypersensitivity reaction was noted in 2 healthy calves treated with A180 in a laboratory study. In one location of a multi-site field trial, one out of the 41 calves treated with 6 mg/kg q 48 hours showed lameness on Day 6 only. In this same field trial location one of 38 calves treated with 8 mg/kg once became lame 4 days after treatment and remained lame on the last day of the study (Day 10). Another calf in the same treatment group developed lameness on the last day of the study.

**STORAGE INFORMATION:** Store at or below 30°C (86°F). Protect from light. Protect from freezing. The color is yellow to amber and does not affect potency.

HOW SUPPLIED: A180 (180 mg danofloxacin/mL) is supplied in 100- and 250-mL, amber-glass, sterile, multidose vials.

Distributed by:

NADA #141-207, Approved by FDA



Animal Health

Exton, PA 19341, USA Div. of Pfizer Inc NY, NY 10017

**Use Only as Directed** 

To report suspected adverse effects, and/or obtain a copy of the MSDS, call 1-800-366-5288.

## Table of Contents

I

A Flowchart for Evaluating Dairy Cow Freestalls-Ken Nordlund, Nigel B. Cook	89
Comparative Efficacy of a Novel Intramammary Dry Cow Antibiotic to Eliminate Subclinical Mastitis	
in the Dry Period-R. T. Dingwell, T. F. Duffield, K. E. Leslie, G. P. Keefe, L. DesCoteaux, P. Dick,	
R. Bagg	98
Case Report–Herd Investigation into the Role of <i>Pasteurella multocida</i> in an Outbreak of Mastitis–	
Michael J. Maroney, Pamela L. Ruegg	108
Cystic Ovarian Follicles in Cattle: A Review-Abdelsalam Q. Talafha, Zuhair A. Bani Ismail,	
Augustine T. Peter	114
Review: Neospora caninum-induced Abortion in Cattle-R.L. Larson, D.K.Hardin	121
High Production and Health: A Curious Paradox-John Fetrow, Steve Eicker	128
Use of Antibiotics to Prevent Calf Diarrhea and Septicemia-Peter D. Constable	
Case Report-Clinical Response to Treatment of Pododermatitis Circumscripta (Ulceration of the Sole)	
in Dairy Cows—SR van Amstel, JK Shearer, FL Palin	143
Diagnostic Complications from "Fecal" Trichomonads-Clell V. Bagley, Michael E. Paskett	
A Review of the Relationship Between Persistent Infection of Cattle with Bovine Viral Diarrhea Virus	
and Feedlot Morbidity and Gain—Larry Moczygemba	155
Urinary Tract Disease, Weight Loss and Death Possibly Related to Winter Browsing of a Shrubby Plant	
(Cistus salviifolius) in Three Herds of Portuguese Beef Cattle-Miguel Saraiva Lima,	
Maria Conceicao Peleteiro, Manuel Malta, A. Brito Pais, Charles A. Hjerpe	162
Use of Expected Progeny Difference (EPD) Information to Estimate Maximum Bid Price For Purchased	
Beef Bulls-Thomas R. Kasari, Michael R. Kinney	179

### Advertisers Index

Biocor Animal Health	
Elanco Animal Health	Back of Book, Inside Back Cover
Intervet	Front of Book, 97
Pfizer Animal Health	Inside Front Cover, Front of Book, 107,
	113, 120, Back of Book, Outside Back Cover

Cover photo by Tim Sheeley, Hillsboro, Ohio, compliments of the Ohio Cattlemen's Association.

The abstracts were translated in French by Guy Beauchamp and revised by Emile Bouchard.

### Table of Coments

# Your Decision to Use Vision<sup>®</sup> Today, Will Ensure Quality Beef Tomorrow.

n an an an an Anna an A Anna an Anna an



### Vision with Spur<sup>®</sup>Adjuvant: Proven Blackleg Protection with Less Reaction, More Performance, and Better Beef.

The facts speak for themselves: **Vision** clostridial vaccines with Spur adjuvant in a 2 mL, subcutaneous dose provide the highest level of immunization with the lowest level of injection-site blemishes. Plus, when compared to conventional blackleg vaccines, you can expect less stress on your cattle – resulting in greater weaning weights and better feed consumption.\* And with over 200 million cattle protected since its introduction, **Vision** remains the product of choice for cattlemen dedicated to raising quality cattle for quality beef. Make the right decision. Ask your veterinarian or animal health supplier for **Vision** today.

P.O. Box 318 • 405 State Street • Millsboro, Delaware 19966 • www.intervetusa.com • 800.441.8272

EXPECT MORE

© Copy

right American Association of Bo

\*Intervet Technical Bulletin 93-3 Vision Feed Consumption and Feed Reactivity Trial. Intervet Technical Bulletin 93-15 Weight Comparison at Weaning in 5 Beef Herds Comparing Vision (2mL) to 5 mL 7-way Administered at Spring Branding. Vision and Spur are registered trademarks of Intervet Inc. ©2003 Intervet Inc. • 1/03 O&B